Provided by Tiger Trade Technology Pte. Ltd.

Mirum Pharmaceuticals, Inc.

89.78
-1.9700-2.15%
Post-market: 89.780.00000.00%19:48 EDT
Volume:1.17M
Turnover:104.80M
Market Cap:5.42B
PE:-191.02
High:91.24
Open:90.04
Low:87.84
Close:91.75
52wk High:109.28
52wk Low:36.88
Shares:60.34M
Float Shares:39.99M
Volume Ratio:1.27
T/O Rate:2.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4700
EPS(LYR):-0.4700
ROE:-8.65%
ROA:-1.83%
PB:17.22
PE(LYR):-191.02

Loading ...

BRIEF-Mirum Pharmaceuticals Files For Offering Of Up To 8.96 Million Shares Of Common Stock By The Selling Stockholders

Reuters
·
Feb 26

Mirum Pharmaceuticals Inc Files for Offering of up to 8.96 Mln Shares of Common Stock by the Selling Stockholders - SEC Filing

THOMSON REUTERS
·
Feb 26

Earnings Flash (MIRM) Mirum Pharmaceuticals Posts Q4 Revenue $148.9M, vs. FactSet Est of $142.5M

MT Newswires Live
·
Feb 26

Mirum Pharmaceuticals Q4 Sales $148.932M Beat $141.806M Estimate

Benzinga
·
Feb 26

Mirum Pharmaceuticals 2025 sales rise

Reuters
·
Feb 26

BRIEF-Mirum Pharmaceuticals Q4 Operating Expenses USD 153.499 Million

Reuters
·
Feb 26

Mirum Pharmaceuticals Inc: Volixibat Vistas Study in Psc Topline Data Expected Q2 2026

THOMSON REUTERS
·
Feb 26

Mirum Pharmaceuticals Inc - 2026 Expected Global Net Product Sales of $630 Million to $650 Million

THOMSON REUTERS
·
Feb 26

Is It Too Late To Consider Mirum Pharmaceuticals (MIRM) After A 108% One Year Rally?

Simply Wall St.
·
Feb 25

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Reuters
·
Feb 24

Travere Q4 product sales surge on FILSPARI growth

Reuters
·
Feb 20

Assessing Mirum Pharmaceuticals (MIRM) Valuation After Recent Share Price Momentum And Rare Disease Growth Prospects

Simply Wall St.
·
Feb 19

Mirum Pharmaceuticals Inc. updates financial calendar

Reuters
·
Feb 19

Mirum Can Sustain Revenue Growth with Multiple Catalysts, RBC Says

MT Newswires Live
·
Feb 18

Mirum Pharmaceuticals Director Saira Ramasastry Reports Sale of Common Shares

Reuters
·
Feb 18

Mirum Pharmaceuticals Grants Stock Options and Equity Awards to New Employees

Reuters
·
Feb 11

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Feb 11

Mirum Pharmaceuticals Announces Health Canada Authorization of Livmarli® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients With Alagille Syndrome

THOMSON REUTERS
·
Feb 05

Health Canada genehmigt LIVMARLI von Mirum Pharmaceuticals zur Behandlung von cholestatischem Pruritus bei PFIC

Reuters
·
Feb 05

Mirum Pharmaceuticals Announces Health Canada Authorization of Livmarli® for the Treatment of Cholestatic Pruritus in Patients With Progressive Familial Intrahepatic Cholestasis (Pfic)

THOMSON REUTERS
·
Feb 05